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Summary
Background Prader–Willi syndrome (PWS) is known for
hyperphagia with impaired satiety and a specific behavioural
phenotype with stubbornness, temper tantrums, manipulative
and controlling behaviour and obsessive–compulsive features.
PWS is associated with hypothalamic and oxytocinergic dysfunc-
tion. In humans without PWS, intranasal oxytocin administra-
tion had positive effects on social and eating behaviour, and
weight balance.
Objective and hypotheses To evaluate the effects of intrana-
sal oxytocin compared to placebo administration on social beha-
viour and hyperphagia in children with PWS.
Design Randomized, double-blind, placebo-controlled, cross-
over study in a PWS Reference Center in the Netherlands.
Method Crossover intervention with twice daily intranasal oxy-
tocin (dose range 24-48 IU/day) and placebo administration,
both during 4 weeks, in 25 children with PWS (aged 6 to 14
years).
Results In the total group, no significant effects of oxytocin on
social behaviour or hyperphagia were found, but in the 17 chil-
dren younger than 11 years, parents reported significantly less
anger (P = 0001), sadness (P = 0005), conflicts (P = 0010)
and food-related behaviour (P = 0011), and improvement of
social behaviour (P = 0018) during oxytocin treatment com-
pared with placebo. In the eight children older than 11 years,
the items happiness (P = 0039), anger (P = 0042) and sadness
(P = 0042) were negatively influenced by oxytocin treatment
compared to placebo. There were no side effects or adverse
events.
Conclusions This randomized, double-blind, placebo-con-
trolled study suggests that intranasal oxytocin administration has
beneficial effects on social behaviour and food-related behaviour
in children with PWS younger than 11 years of age, but not in
those older than 11 years of age.
(Received 25 April 2016; returned for revision 13 June 2016; finally
revised 18 July 2016; accepted 31 July 2016)
Introduction
Prader–Willi syndrome (PWS) is characterized by neonatal
hypotonia with suckling problems, early onset of hyperphagia
with impaired satiety, endocrine disturbances and a specific
behavioural phenotype with stubbornness, temper tantrums,
manipulative and controlling behaviour, obsessive–compulsive
features and difficulties in changing routines.1–3 This results
from the absence of expression of the paternally derived genes
located on chromosome 15 at the locus q112-13, caused by a
paternal deletion, maternal uniparental disomy, imprinting cen-
tre disorder or paternal chromosomal translocation.1 One of the
nonexpressed genes in this region is MAGEL2.
MAGEL2-deficient mice have a major reduction of oxytocin
in the hypothalamus and an altered onset of suckling activity
resulting in impaired feeding and 50% mortality.4 Injection of a
specific oxytocin receptor antagonist in wild-type mouse pups
resulted in a similar feeding deficiency as seen in MAGEL2
mutants.4 Administration of oxytocin to MAGEL2-deficient
mouse pups 3–5 h after birth normalized suckling and feeding
behaviour and rescued all of them.4 Human newborns with
PWS show similar suckling problems as found in the MAGEL2-
deficient mice, which suggests that the lack of MAGEL2 gene
might play a role in the suckling deficit seen in PWS newborns.
In adult patients with PWS, the number of oxytocin-expres-
sing neurons in the hypothalamus was significantly decreased by
42% and plasma levels of oxytocin were relatively low in relation
to their obesity.5,6 However, in 23 children with PWS between 5
and 11 years of age, high plasma levels of oxytocin were
reported.7 Altogether, the oxytocin system in patients with PWS
appears to be dysfunctional.
Oxytocin is known to be involved in food intake,8,9 body
weight10,11 and social skills,12 all of which are seriously affected
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in patients with PWS. The majority of patients with PWS have
hyperphagia with impaired satiety, and they are severely at risk
to become obese. They show symptoms of autistic spectrum dis-
order (ASD) and 36% of them fulfil the criteria of ASD.13 Social
cognitive functioning is markedly reduced, which has major
consequences for the family and surrounding and for the
approach of patients with PWS.14,15 Currently, there are no
treatment options for the hyperphagia and social behavioural
problems of patients with PWS, but the oxytocin system is a
promising target. Studies on intranasal oxytocin administration
showed that oxytocin reduced body weight of obese non-PWS
patients.10 Also, a single oxytocin gift improved emotion recog-
nition in healthy and autistic adults16,17 and reduced repetitive
behaviours in those with ASD.18
Only two studies have investigated the effects of oxytocin
treatment in PWS. Tauber et al. administrated a single gift of
24 IU intranasal oxytocin to 24 adults with PWS. After two
days, they showed increased trust in others and decreased sad-
ness tendencies with less disruptive behaviour.19 In the placebo-
controlled crossover study by Einfeld et al., 22 individuals with
PWS aged 12–30 years received 18–40 IU intranasal oxytocin
twice daily during 8 weeks, but they showed no benefit in the
target behaviours or weight.20
Given the possible dysfunction of the oxytocin system in PWS
and the involvement of oxytocin in socials skills, food intake
and body weight, we hypothesized that oxytocin supplementa-
tion in children with PWS would improve social behaviour and
hyperphagia. We therefore investigated the effects of intranasal
oxytocin administration on social behaviour, food intake and
satiety in children with PWS in a randomized, double-blind, pla-
cebo-controlled, crossover study.
Methods
Subjects
To be eligible to participate in this study, subjects (1) had a
genetically confirmed diagnosis of PWS, (2) were aged 6 to
14 years, (3) had social behavioural problems and/or a pre-
occupation with food, (4) were na€ıve for oxytocin treatment at
time of enrolment and (5) used growth hormone therapy for
at least 1 year and were still receiving it. Exclusion criteria
were (1) severe psychiatric problems such as psychosis, serious
illness or cardiac abnormalities; (2) allergic reactions or hyper-
sensitivity to oxytocin; (3) medication to reduce weight (fat)
other than GH; and (4) noncooperative behaviour resulting in
inability to comply with intranasal administration and/or hos-
pital visits.
Forty-two children with PWS were eligible. Parents of 17 chil-
dren refused to participate; ten due to too large burden, five due
to practical issues and two because the children themselves did
not want to participate. The study group consisted of 25 chil-
dren (14 boys, 11 girls) with PWS, aged 6–14 years. GH therapy
was prescribed at an initial dose of 1 mg/m2/day, and dose was
lowered in case of high IGF-I levels. One child used levothyrox-
ine and another used citalopram and aripiprazole.
Design
A randomized, double-blind, placebo-controlled, crossover study
was conducted to investigate the effects of intranasal oxytocin
administration on social behaviour, food intake and satiety.
Children received either oxytocin or placebo for 4 weeks, after
which they crossed over to the alternative treatment for a further
4 weeks. No washout period was implemented, as the half-life
time of oxytocin is only 3–20 min. An independent statistician
generated the random allocation sequence and only he and the
independent pharmacist were unblinded. The children were
stratified according to gender and age (6–1099 or
11–1499 years) and then randomly and blindly assigned to
receive intranasal administration twice daily, before breakfast
and dinner, of either oxytocin (Syntocinon, 4 IU/puff, Sigma
Tau) or identical appearing placebo (placebo, 0 IU/puff, Sigma
Tau). The dose was based on doses used in other trials12,20 and
calculated according to body surface: a child of 08–115 m2
received 2dd3 puffs (12 IU twice daily); 115–145 m2 had 2dd4
puffs (16 IU twice daily); 145–175 m2 had 2dd5 puffs (20 IU
twice daily); and of >175 m2 had 2dd6 puffs (24 IU twice
daily).
Measurements
Children were examined at outpatient clinic, at baseline, after
4 weeks and after 8 weeks. Standing height was measured with a
calibrated Harpenden stadiometer, and weight was determined
on a calibrated scale (Servo Balance). Height, weight and BMI
were expressed as SDS according to Dutch reference data,
adjusted for age and sex.21,22 Percentage fat was measured by
DXA (Lunar Prodigy; GE Healthcare). All scans were made on
the same machine, and daily quality assurance was performed.
Blood samples were collected in the morning after 12-h over-
night fast. Samples were quickly frozen on dry ice and stored at
80 °C until assayed. A breakfast meal consisting of 270 grams
(560 kcal) industrially produced multigrain pancakes cut into
pieces was used to examine the food intake and satiety. This
amount was determined in collaboration with a dietitian; weight
was 150%, and calorie-intake 185% of a normal healthy break-
fast for a child with PWS. After blood collection, the fasted chil-
dren were instructed to eat as much as they wished of the meal.
The weight of the plate with pancakes was measured at baseline
and after the child finished eating. Besides, the duration of eat-
ing was determined. The child stayed in the room together with
the investigator, while their parents waited elsewhere.
Social and eating behaviour were carefully monitored by the
parents at home and investigated by two parent questionnaires.
Dykens Hyperphagia Questionnaire was used to determine
(changes in) eating behaviour and hyperphagia.23 Although the
Dykens Hyperphagia Questionnaire is validated, we have experi-
ence that not all items of this questionnaire are applicable nowa-
days. The new generation of children with PWS had an early
diagnosis and received intensive support from (para)medics, and
started with GH treatment at a young age, which has markedly
changed the phenotype, but they are still pre-occupied with
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food. Therefore, the Oxytocin Study Questionnaire was devel-
oped by three physicians and a psychologist, all very experienced
in PWS. The questionnaire unravels (changes in) emotions,
social and eating behaviour and possible side effects. Parents
were asked to fill in the applicable change from 3 (much less
frequently) to +3 (much more frequently), in which 0 was ‘no
difference’. An example of a question is ‘In the last 4 weeks, my
child was. . .sad’. Comparable questions were asked regarding
being angry, being happy, showing food-seeking behaviour, hav-
ing conflicts with others, etc.
Assays
All blood samples were determined in the same laboratory
according to a standardized procedure. Levels of serum crea-
tinine, hepatic enzymes and glucose were measured with COBAS
8000 systems of Roche, and thyroid function was measured with
Vitros ECIQ immunoanalyzer system of Ortho Clinical Diagnos-
tics. Oxytocin levels in blood samples were measured in duplo
with an oxytocin ELISA kit (Enzo Life Sciences). To assure the
content of the vials, one puff per child per phase was measured
by the same oxytocin ELISA kit. In summary, all children had
one vial with and one vial without oxytocin, which confirmed
perfect execution of the randomization.
Statistics
Statistical analysis was performed by SPSS version 23.0. Calcu-
lation of the sample size was based on the Oxytocin Study
Questionnaire. Parents answer questions about changes in eat-
ing behaviour and social behaviour, from 3 (much less fre-
quently) to +3 (much more frequently), in which 0 was ‘no
difference’. A decrease of four points was considered clinically
relevant. Based on an SD of four, a power of 09 and signifi-
cance level of 005, a total of 24 patients had to enter the two-
treatment crossover study. Data were not normally distributed;
therefore, nonparametric tests were used and data are expressed
as median (interquartile range (IQR)) unless otherwise stated.
Statistical analysis appropriate for crossover trials was used,
taking into account any carry-over or treatment-period effect,
calculated by Wilcoxon signed rank test and Mann–Whitney
U-tests, but these were not found. Depending on the data,
results of the visit (i.e. questions about changes) or differences
(Δ) between visit one and two, and between visit two and
three (i.e. Δweight) were used. The effect of oxytocin vs pla-
cebo was tested by Wilcoxon tests in case of continuous data
and McNemar tests in case of binary data. Correlations
between effect of oxytocin or oxytocin levels and other param-
eters were assessed using Spearman’s rho. Differences were con-
sidered significant if P-value was <005.
Study approval
Written informed consent was obtained from parents and from
children older than 12 years; assent was obtained in children
younger than 12 years. The study protocol was approved by the
Medical Ethics Committee of Erasmus University Medical Cen-
ter, the Netherlands, and registered at Nederlands Trial Register
NTR4950 (www.trialregister.nl).
Results
Baseline characteristics
Table 1 shows the baseline characteristics of the 25 children
with PWS who were included between January and September
2015. Median age was 93 (range 60–137) years, and BMI was
24 (07–43) SDS. Thirteen (52%) patients had a deletion and
12 (48%) an mUPD. All received GH treatment with a median
dose of 08 (06–10) mg/m2/day (0024 mg/kg/day), started at
a median age of 13 (10–22) years, with a median duration of
GH treatment of 80 (57–92) years. The median dose of oxy-
tocin was 16 IU (range 12–24) twice daily. All 25 children com-
pleted the study.
Effects on social behaviour, food intake and satiety
In the total group of 25 children with PWS between 6 and
14 years of age, no effects of oxytocin vs placebo treatment were
found on social behaviour, food intake and satiety. In contrast
to these nonsignificant effects of oxytocin in the total group,
correlation analyses showed that a younger age was strongly
associated with beneficial effects of oxytocin treatment on social
and eating behaviour (q=0553, P = 0004 and q=0485,
P = 0014, resp.), and therefore, subanalyses were performed. In
line with the stratification, we divided the total group in 17
patients younger than 11 years and eight patients older than
11 years.
Subanalysis in the younger children
Effects on social behaviour. Parents filled out questionnaires
about their child. The items anger, sadness and conflicts
improved significantly during oxytocin treatment compared to
placebo (P = 0001, P = 0005 and P = 0010, resp.) (Table 2,
Fig. 1). The total Oxytocin Study Questionnaire score showed a
significant improvement of 4 (75 to 1) points during
oxytocin treatment compared to placebo (P = 0001). Ten of 17
(588%) parents reported an improvement in social behaviour
during oxytocin treatment, while four (235%) parents reported
improvement during placebo (P = 0059).
Effects on eating behaviour. The 17 younger children showed a
significant improvement in food-related behaviour during
oxytocin treatment (P = 0011). During 4 weeks of oxytocin
treatment, food-seeking behaviour and satiety remained similar
(P = 0429 and P = 0713, resp.); however, at baseline, food-
seeking behaviour was only reported by six (353%) of the 17
parents, and in three of them, food-seeking behaviour was seen
a few times per year. In both phases, almost all children finished
their standardized breakfast meal. Only three children left
pancakes (median 95, range 70–140 gram) during oxytocin
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treatment and one of them also left 88 grams during placebo.
During the standardized breakfast meal, the rate and duration of
eating was similar during oxytocin and placebo treatment (238
vs 229 gram/min, P = 0887 and 116 vs 105 min, P = 0102)
(Table 2).
The difference in weight, BMI and fat percentage between
start and end (Δ) of the 4 weeks of oxytocin treatment was sim-
ilar as during placebo (P = 0055, P = 0149 and P = 0136,
resp.).
Subanalyses in the older children
Effects on social behaviour. We did not find beneficial effects of
oxytocin in the eight children older than 11 years (Table 2). The
items happiness, anger and sadness were negatively influenced
by oxytocin treatment compared to placebo (P = 0039,
P = 0042 and P = 0042, resp.). The Oxytocin Study
Questionnaire showed an unfavourable score of +15 (03–5)
points during oxytocin treatment compared to placebo
Table 1. Baseline characteristics of total group and per treatment schedule
Total group of patients of 6 to 14 years
PWS (n = 25) Oxytocin / Placebo (n = 11) Placebo / Oxytocin (n = 14) P*
Gender 14 boys, 11 girls 6 boys, 5 girls 8 boys, 6 girls
Genetic subtype (DEL/mUPD) 13 / 12 6 / 5 7 / 7
Age (yrs) 93 (69 to 119) 90 (64 to 112) 103 (70 to 125) 0403
Height for age (SDS) 08 (02 to 16) 12 (04 to 17) 05 (00 to 11) 0222
Weight for height (SDS) 20 (06 to 41) 23 (03 to 61) 19 (10 to 41) 0809
BMI for age (SDS) 24 (07 to 43) 24 (01 to 63) 22 (12 to 39) 1000
Age at start GH treatment (yrs) 13 (10 to 22) 13 (09 to 22) 15 (10 to 26) 0609
Duration of GH treatment (yrs) 80 (57 to 92) 73 (53 to 90) 82 (59 to 93) 0687
GH dosage (mg/m2/day) 08 (06 to 10) 08 (05 to 10) 08 (06 to 10) 0851
Prepubertal/pubertal 16 / 9 7 / 4 9 / 5
Patients of 6 to 11 years
PWS (n = 17) Oxytocin / Placebo (n = 8) Placebo / Oxytocin (n = 9) P*
Gender 9 boys, 8 girls 4 boys, 4 girls 5 boys, 4 girls
Genetic subtype (DEL/mUPD) 9 / 8 4 / 4 5 / 4
Age (yrs) 73 (64 to 97) 78 (61 to 93) 73 (67 to 103) 0606
Height for age (SDS) 05 (00 to 13) 12 (00 to 16) 03 (02 to 08) 0277
Weight for height (SDS) 17 (06 to 39) 17 (04 to 53) 17 (09 to 39) 0743
BMI for age (SDS) 19 (06 to 39) 21 (00 to 57) 18 (10 to 36) 0963
Age at start GH treatment (yrs) 13 (09 to 17) 13 (08 to 20) 12 (09 to 15) 0743
Duration of GH treatment (yrs) 63 (53 to 84) 63 (52 to 82) 63 (55 to 88) 0541
GH dosage (mg/m2/day) 07 (05 to 10) 07 (05 to 10) 07 (05 to 10) 0963
Prepubertal/pubertal 14 / 3 6 / 2 8 / 1
Patients of 11 to 14 years
PWS (n = 8) Oxytocin / Placebo (n = 3) Placebo / Oxytocin (n = 5) P*
Gender 5 boys, 3 girls 2 boys, 1 girl 3 boys, 2 girls
Genetic subtype (DEL/mUPD) 4 / 4 2 / 1 2 / 3
Age (yrs) 125 (116 to 137) 123 (118 to 130) 126 (119 to 137) 0393
Height for age (SDS) 12 (06 to 16) 16 (11 to 18) 10 (02 to 16) 0571
Weight for height (SDS) 22 (06 to 43) 23 (04 to 46) 20 (08 to 43) 1000
BMI for age (SDS) 28 (09 to 56) 32 (13 to 55) 25 (12 to 54) 1000
Age at start GH treatment (yrs) 27 (18 to 43) 22 (16 to 29) 29 (21 to 49) 0393
Duration of GH treatment (yrs) 95 (85 to 111) 99 (95 to 106) 85 (82 to 110) 0393
GH dosage (mg/m2/day) 10 (07 to 10) 09 (08 to 10) 10 (07 to 10) 0786
Prepubertal/pubertal 2 / 6 1 / 2 1 / 4
*P-value at baseline between the two-treatment schedules.
Data expressed as median with interquartile range.
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(P = 0027). Three (375%) parents reported a deterioration of
social behaviour during oxytocin treatment, while four (50%)
parents reported an improvement during placebo treatment
(P = 0038).
Effects on eating behaviour. During oxytocin treatment, food-
related behaviour, food-seeking behaviour and satiety remained
similar (P = 0066, P = 0102 and P = 0317, resp.) in the
children older than 11 years. In both treatment phases, all
Table 2. Effects on social behaviour and hyperphagia of children younger and older than 11 years
Patients of 6 to 11 years Patients of 11 to 14 years
Items investigated Oxytocin phase Placebo phase P* Oxytocin phase Placebo phase P*
Improvement social
behaviour (n=)
10 of 17 4 of 17 0059 0 of 8 4 of 8 0038
Questionnaires about
social behaviour
Better Same Worse Better Same Worse Better Same Worse Better Same Worse
Happiness 6 10 0 2 14 1 0344 0 7 1 5 3 0 0039
Anger 11 6 0 0 10 7 0001 0 4 4 5 3 0 0042
Sadness 9 8 0 0 12 5 0005 0 5 3 5 3 0 0042
Conflicts 7 9 0 1 12 4 0010 0 5 3 3 5 0 0068
Social interaction 2 15 0 3 12 2 0450 0 6 2 3 5 0 0066
Disruptive behaviour 4 13 0 1 13 3 0071 0 5 3 2 6 0 0109
Improvement eating
behaviour (n=)
6 of 17 2 of 17 0096 1 of 8 3 of 8 0157
Standardized breakfast meal
Did not finished meal
completely (n=)
3 of 17 1 of 17 0109 0 of 8 0 of 8 1000
Rate of eating (gram/min) 238 (158 to 295) 229 (146 to 290) 0887 238 (140 to 596) 245 (174 to 525) 0779
Duration of eating (min) 105 (88 to 145) 116 (93 to 185) 0102 120 (44 to 211) 116 (53 to 156) 0889
Measurements
Δweight (kg) 03 (01 to 06) 03 (05 to 00) 0055 05 (02 to 12) 04 (00 to 07) 0833
ΔBMI (kg/m2) 01 (03 to 02) 02 (03 to 00) 0149 00 (01 to 00) 01 (02 to 03) 0327
Δfat percentage by DXA
scan
07 (09 to–01) 01 (06 to 11) 0136 05 (01 to 09) 01 (08 to 03) 0092
Questionnaires about food Better Same Worse Better Same Worse Better Same Worse Better Same Worse
Food-related behaviour 7 10 0 1 9 7 0011 0 7 1 3 5 0 0066
Food-seeking behaviour 1 15 1 1 13 3 0713 0 7 1 0 8 0 0317
Satiety 4 11 1 2 14 1 0429 0 7 1 2 6 0 0102
Dykens hyperphagia 8 8 1 3 11 3 0285 0 7 1 3 5 0 0068
Data expressed in number or median (IQR); *P-value between oxytocin and placebo phase, bold values are statistically significant (p<0.05).
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Fig. 1 Effect of 4 weeks oxytocin vs placebo
treatment on six items of social behaviour in
children with PWS younger than 11 years of age.
Individual differences between oxytocin and
placebo treatment are presented as a black dot, and
the black horizontal lines display the median
difference. In case of a significant difference
between the oxytocin and placebo phase, P-values
are given.
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children finished their standardized breakfast meal, while the
rate and duration of eating was similar during oxytocin and
placebo treatment (238 vs 245 gram/min, P = 0779 and 120
vs 116 min, P = 0889) (Table 2). Δweight, ΔBMI and Δfat
percentage were similar in the two phases (all P > 0092).
Associations
There were no significant differences in oxytocin vs placebo
effects between boys and girls, between children with a deletion
or mUPD, or between children with or without serious beha-
vioural problems. The effects of oxytocin treatment were not
associated with baseline BMI or BMI SDS. In the total group,
the association between age and social and eating behaviour dur-
ing oxytocin treatment was stronger than the association
between pubertal stage and these outcomes (q=0553,
P = 0004 and q=0485, P = 0014 vs q=0452, P = 0023
and q=0396, P = 0050, resp.).
Oxytocin levels in blood
Serum oxytocin levels before and during study were determined
to further unravel the different effects in younger and older chil-
dren (Fig. 2). At baseline, children younger than 11 years had a
median fasting oxytocin level of 3156 (1864–5325) pg/ml, and
12–14 h after the last oxytocin dose after 4 weeks of treatment it
was 4685 (2809–9490) pg/ml (P = 0134). Children older than
11 years had a baseline fasting oxytocin level of 2692 (1737–
3754) pg/ml, and 4750 (1976–7831) pg/ml after oxytocin treat-
ment (P = 0327).
In the younger children, lower oxytocin levels after 4 weeks of
oxytocin treatment were associated with positive effects on social
behaviour (q=0540, P = 0027). This association was not found
in older children. Baseline oxytocin levels or change in oxytocin
levels during treatment was not associated with positive effects.
Only one patient older than 11 years had benefit from oxy-
tocin treatment. Remarkably, this patient had the highest base-
line oxytocin level of patients older than 11 years, which
decreased considerably to the lowest level of 1126 pg/ml during
oxytocin treatment (Fig. 2). The other older patients without
benefit had lower baseline oxytocin levels (Fig. 2), which
increased or only slightly decreased during oxytocin treatment.
Dosing
The oxytocin/placebo dose was based on body surface (see
Methods). In the total group, median dose was 16 IU (12–20)
twice daily, which was 123 (120–133) IU/m2 and 039 (034–
044) per kilogram body weight (IU/kg). Given the different
effects of oxytocin in the younger and older group of patients,
the correlation between dosage and age was investigated. The
dose in IU/m2 did not correlate with age, but the given dose
recalculated as IU/kg correlated inversely with age (q=0663,
P < 0001), meaning that older patients received a lower dose
when recalculated in IU/kg (Fig. 3). The median dose was 042
(037–045) IU/kg in the children younger than 11 years and
034 (030–037) IU/kg in the older children (P = 0002).
Remarkably, the only patient older than 11 years, who had bene-
fit from oxytocin treatment, had one of the lowest recalculated
doses in IU/kg of the older patients and the lowest dose in IU/kg
of all patients with beneficial effects of oxytocin.
Safety parameters
The intranasal administration of oxytocin was very well toler-
ated, and there were no side effects. Renal function, hepatic
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Fig. 2 Fasting serum oxytocin levels at baseline in pg/ml per age.
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○ represents a patient without effect of oxytocin treatment. x represents
a patient with negative effect of oxytocin treatment. The grey line
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enzymes, thyroid function and glucose remained stable and nor-
mal for all patients, as did the systolic blood pressure. Diastolic
blood pressure was lower during oxytocin treatment (median 64
vs 73 mmHg, P = 0008), but within normal limits. Similar
results were found in patients younger or older than 11 years.
Discussion
Our randomized, double-blind, placebo-controlled, crossover
study is the first oxytocin study in children with PWS aged
between 6 and 14 years. Although there were no effects in the
group as a whole, subanalyses demonstrated that children with
PWS between 6 and 11 years had beneficial effects of intranasal
oxytocin administration on social behaviour and hyperphagia.
Their parents reported significantly less anger, sadness, conflicts
and food-related behaviour, and improvement of social beha-
viour during oxytocin treatment compared with placebo. In chil-
dren with PWS, older than 11 years were the beneficial effects of
oxytocin on social behaviour and hyperphagia not found. We
did not find side effects or adverse events.
Until now, there have been no effective treatment options for
behaviour and food-related problems in PWS. Our study suggests
that intranasal oxytocin administration is a novel and promising
treatment for young children with PWS. Children with PWS have
a specific behavioural phenotype with stubbornness, temper tan-
trums, manipulative and controlling behaviour, obsessive–com-
pulsive features and difficulties in changing routines.1–3 The social
behavioural problems and hyperphagia seriously affect the quality
of life of the children and their parents and caretakers.
Nowadays, most parents of children with PWS have made all
kind of adjustments in everyday life to limit access to food, such
as locks on the fridge.24 This explains why, prior to the study,
children had a low prevalence of food-seeking behaviour. It is
therefore not surprising that we found no effects of oxytocin on
food-seeking behaviour. However, the baseline food-related
behaviour scores show that these children are still pre-occupied
with food, characterized by talking about food, asking for food,
playing that they are cooking, etc., despite all the adjustments to
control hyperphagia. Oxytocin treatment decreased this food-
related behaviour, which argues that oxytocin has an inhibiting
effect on the hyperphagia, despite the lack of effects on food-
seeking behaviour and satiety. Studies on the long-term effects
of 4 weeks treatment and also long-term oxytocin treatment tri-
als are warranted to confirm our findings on efficacy and safety.
In contrast to the beneficial effects of oxytocin in the younger
children, no positive effects were found in children with PWS
older than 11 years. Some parents of the older subgroup even
reported negative effects of oxytocin on social behaviour, espe-
cially regarding happiness, anger and sadness, in contrast to
none of the parents of younger children. These findings are in
line with the results of an 8-week oxytocin trial in 22 individuals
with PWS between 12 and 29 years,20 in which no benefits in
target behaviours or weight were found. The only significant dif-
ference found in that study was an increase in temper outbursts
when the oxytocin dose was increased. Tauber et al. reported
positive effects of oxytocin on social behaviour in adults with
PWS, but comparison is difficult because they investigated a sin-
gle dose of intranasal administration.19
We measured plasma oxytocin levels prior and during the oxy-
tocin trial. At baseline, oxytocin levels in children with PWS
younger than 11 years showed high interindividual variability, in
line with findings in children with PWS of similar age by Johnson
et al.,7 and there was no relation between baseline oxytocin levels
and positive effects during treatment. In contrast, a lower oxytocin
level after 4 weeks of oxytocin treatment was associated with
stronger positive effects on social behaviour, suggesting that it is
beneficial for young children to have a lower plasma oxytocin level
during oxytocin treatment. Those older than 11 years had, how-
ever, lower and less widespread baseline oxytocin levels and their
levels increased during oxytocin treatment. The only older boy
with beneficial effects of oxytocin treatment had a declining oxy-
tocin level during treatment, like most of the younger children.
Why did the oxytocin treatment work in the younger, but not
in the older children? One explanation could be that mistakes
had been made in the preparation or delivery of the intranasal
sprays in the older children. For that reason, an independent
laboratory measured the content of the vials and was able to
reject that explanation. Second, it could be that the sample size
of the older subgroup was too small to show significant changes,
but that argument is unlikely as several significant negative
effects of oxytocin administration were found in the older sub-
group. Third, there could have been a dosing issue. We calcu-
lated the oxytocin doses according to body surface, a common
way of hormone dosing in children, which resulted in a rela-
tively lower dose in IU/kg in children older than 11 years. How-
ever, an inappropriately low dose is also an unlikely explanation,
as the only older boy with positive effects of oxytocin had the
second lowest dose of all children in IU/kg. Besides, Einfeld et al
reported adverse effects of higher oxytocin doses in older
patients.20 A fourth explanation could be that the behaviour and
coping style of older patients with PWS are more embedded in
their personality and are therefore not easy to change. A treat-
ment period of 4 weeks is not short, but it could be that a
longer period than four or 8 weeks of oxytocin treatment might
be needed to induce beneficial effects in older children.
Another, more pathophysiological explanation might be that
older children with PWS have developed an unresponsive oxy-
tocin system over the years, with a lower number of oxytocin
receptors and neurons in the hypothalamus. Adults with PWS
have a 42% decrease in oxytocin neurons in the hypothalamus
and relatively low plasma levels of oxytocin in relation to their
obesity.5,6 One of the nonexpressed genes in the PWS region on
chromosome 15 is MAGEL2. This gene is known to be expressed
in mouse hypothalamus during development and their knockout
alters the number and/or function of oxytocin neurons.25
MAGEL2–knockout pups were not hypotonic, but had an altered
onset of suckling activity resulting in impaired feeding and 50%
mortality,4 while the survivors had deficits in social recognition
and social interaction on the long term.26 These suckling prob-
lems in infancy and social problems later on are similar to chil-
dren with PWS, suggesting that this gene might play a role in the
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suckling and behavioural problems in PWS. Adult MAGEL2–
knockout mice expressed a significantly reduced number of oxy-
tocin receptors in several regions of the brain.26 Children with
PWS, who are MAGEL2 deficient, could therefore be less or non-
responsive to oxytocin treatment when they become older,
because their oxytocin system deteriorated over time. In contrast,
it was shown that daily administration of oxytocin in the first
postnatal week prevents the deficits in social behaviour in the
adult mutant mice and partly restore a normal oxytocin system in
the brain. This suggests that the postnatal period is a critical per-
iod for the oxytocin system in which social behaviour is pro-
grammed. Nevertheless, our study shows that oxytocin treatment
has beneficial effects in children with PWS until the age of
approximately 11 years, thus also beyond the postnatal period.
It is remarkable that the changeover in oxytocin effects occurred
around the age of 11 years, the time of puberty onset. We previ-
ously demonstrated that GH-treated children with PWS have a
normal age at onset of puberty, but that the majority shows a dete-
rioration in pubertal development after Tanner stage 2–3 with a
decline in gonadal function in boys.27–29 It might be that the reac-
tivation of the GnRH axis just before the onset of puberty together
with the lack of expression of MAGEL2 and other yet unknown
genes, not only result in a rapid gonadal failure after the onset of
puberty but also in an enhanced deterioration of the oxytocin sys-
tem in patients with PWS. We acknowledge that our supposition
is very hypothetical, but we consider it noteworthy to mention
that these processes seem to occur in the same timeframes. Studies
are warranted to further unravel the pathophysiology and to
determine whether others also find the 11-year cut-off for benefit
of oxytocin treatment.
Present study was a placebo-controlled study in which we cal-
culated the dose according to body surface, based on doses used
in other trials.12,20 We did not perform a dose-finding study,
and no washout period was included to limit the number of
hospital visits. We found no differences in food intake during
the breakfast meal test between the oxytocin and placebo phase.
This might be due to the lack of a satiety level in PWS or that
their satiety level was much higher than the maximum amount
of food that we offered,30 but we considered it unethical to pre-
sent an unlimited amount of food as patients with PWS feel
never satiated and have an increased risk of gastric rupture.
In conclusion, administration of intranasal oxytocin appears
to have beneficial effects on social behaviour and food-related
behaviour in children with PWS younger than 11 years of age
without side effects or adverse events. Parents reported signifi-
cantly less anger, sadness, conflicts and food-related behaviour,
and improvement of social behaviour during oxytocin treatment
compared with placebo. In contrast to the younger children with
PWS, those older than 11 years of age did not benefit from
oxytocin treatment.
Author contributions
RJK substantially contributed to conception and design of study,
acquisition of data, analysis and interpretation of data and
drafting the manuscript. SHD substantially contributed to acqui-
sition of data, interpretation of data and critical revision of the
manuscript. AHK substantially contributed to conception and
design of study, analysis and interpretation of data and critical
revisions of the manuscript.
Funding
Independent research grant of Dutch Prader–Willi Fund and
Dutch Growth Research Foundation. Pharmaceutical company
Sigma Tau provided oxytocin nasal spray and identical appear-
ing placebo free of charge.
Acknowledgements
This study was supported by independent research grants of Dutch
Prader–Willi Fund and Dutch Growth Research Foundation.
Sigma Tau provided oxytocin nasal spray and identical appearing
placebo free of charge. The authors thank all the participants and
their parents for their enthusiastic cooperation. The assistance of
Berber Kerkhof, Mari€elle van Eekelen and Eva Mahabier is grate-
fully appreciated and we thank Jose Veen for dietary advice.
Declaration of interest and Financial disclosure
The authors have nothing to disclose.
Key points
• Prader–Willi syndrome (PWS) is known for hyperphagia
with impaired satiety and a specific behavioural phenotype with
stubbornness, manipulative and controlling behaviour and
obsessive–compulsive features. PWS is associated with hypotha-
lamic and oxytocinergic dysfunction.
• In humans without PWS, intranasal oxytocin administra-
tion had positive effects on social and eating behaviour, as well
as weight balance.
• This randomized, double-blind, placebo-controlled, cross-
over study demonstrates that intranasal oxytocin has beneficial
effects on social behaviour and food-related behaviour in chil-
dren with PWS younger than 11 years of age, but not in those
older than 11 years of age.
• Parents of those younger than 11 years reported signifi-
cantly less anger, sadness, conflicts and food-related behaviour,
and improvement of social behaviour during oxytocin treatment
compared with placebo.
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